Researcher
Hans Prenen
- Keywords (University of Antwerp):Medicine
- Disciplines (University of Antwerp):Cancer biology, Cancer diagnosis, Cancer epidemiology, Cancer prevention, Cancer therapy
- Disciplines (KU Leuven):Morphological sciences, Oncology
- See also: Hans Prenen (KU Leuven)
Affiliations
- Center for Oncological Research (CORE) (Research group)
Member
From1 Oct 2020 → Today - Laboratory of Tumor Inflammation and Angiogenesis (VIB-KU Leuven) (Division)
Member
From12 Jul 2017 → 30 Apr 2018 - Clinical Digestive Oncology (Division)
Member
From1 Jan 2012 → 23 Jul 2017 - Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 2009 → 31 Dec 2011
Projects
1 - 2 of 2
- Development of an image-based multiparametric drug response signature to predict clinical therapy response in cancer patients from ex vivo tumoroid screenings.From1 Oct 2022 → TodayFunding: BOF - doctoral mandates
- Reinvigorating the antitumor immunity in human breastand cervical cancer with an innovative RANK(L) targeted combination strategy.From1 Nov 2021 → TodayFunding: Nonprofit institution or equivalents
Publications
41 - 50 of 150
- RNA based approaches to profile oncogenic pathways from low quantity samples to drive precision oncology strategies(2021)
Authors: Anja van de Stolpe, Wim Verhaegh, Jean-Yves Blay, Cynthia X. Ma, Patrick Pauwels, Mark Pegram, Hans Prenen, Dirk De Ruysscher, Nabil F. Saba, Susan F. Slovin, et al.
- Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation(2021)
Authors: Federico Virga, Federica Cappellesso, Benoit Stijlemans, Anne-Theres Henze, Rosa Trotta, Jonas Van Audenaerde, Ananda S. Mirchandani, Manuel A. Sanchez-Garcia, Jolien Vandewalle, Francesca Orso, et al.
- Highlights in digestive oncology(2020)
Authors: Hans Prenen, Timon Vandamme, Marc Peeters
Pages: 183 - 187 - Entrectinib in ROS1 fusion-positive non-small-cell lung cancer(2020)
Authors: Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, Fabrice Barlesi, Matthew G. Krebs, Alice T. Shaw, Filippo de Braud, Christian Rolfo, Myung-Ju Ahn, Juergen Wolf, et al.
Pages: 261 - 270 - Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil(2020)
Authors: Stephanie Detailleur, Eva Segelov, Marzia Del Re, Hans Prenen
Pages: 1 - 5 - Is bodyweight-based dosing truly better than flat dosing for panitumumab? [Response to Letter](2020)
Authors: Michael Z. Liao, Johannes Kast, Marloes Berkhout, Hans Prenen, Sandeep Dutta, Vijay V. Upreti
Pages: 189 - 190 - A multicentre, international, observational study on transarterial chemoembolisation in colorectal cancer liver metastases(2020)
Authors: Philippe L. Pereira, Dirk Arnold, Thierry de Baere, Fernando Gomez, Thomas Helmberger, Roberto Iezzi, Geert Maleux, Hans Prenen, Bruno Sangro, Anders Nordlund, et al.
Pages: 857 - 861 - Practical considerations for treating patients with cancer in the COVID-19 pandemic(2020)
Authors: Eva Segelov, Craig Underhill, Hans Prenen, Christos Karapetis, Christopher Jackson, Louise Nott, Tim Clay, Nick Pavlakis, Sabe Sabesan, Ellen Heywood, et al.
Pages: 467 - 482 - Impact of the COVID-19 epidemic on a pan-Asian academic oncology clinical trial(2020)
Authors: Eva Segelov, Hans Prenen, Daphne Day, C. Raina Macintyre, Estelle Mei Jye Foo, Raghib Ali, Quanyi Wang, Xiaoting Wei, Gilberto de Lima Lopes, Kefeng Ding, et al.
Pages: 585 - 588 - Dose regimen rationale for panitumumab in cancer patients(2020)
Authors: Michael Z. Liao, Marloes Berkhout, Hans Prenen, Sandeep Dutta, Vijay V. Upreti
Pages: 109 - 114